CORDIS
EU research results

CORDIS

English EN
Enhancing CHO by Mammalian Systems Biotechnology (eCHO systems)

Enhancing CHO by Mammalian Systems Biotechnology (eCHO systems)

Objective

Chinese hamster (CHO) ovary cells are the production host for a +50 billion €/yr biopharmaceuticals market. Current CHO production platforms dates to 1980 and are based primarily on media and process optimisation with little consideration to the optimization of the cellular machinery. Fortunately, with the recent sequencing of the CHO genome, an opportunity has opened to significantly advance the CHO platform. The benefit will be advanced production flexibility and a lower production cost.

This ITN graduate training programme - eCHO Systems - will blend conventional molecular, cellular, and synthetic biology with genome scale systems biology training in ‘omics data acquisition, biological network modeling, and genome engineering in three interdisciplinary topics:

1) Acquisition of large scale ‘omics data sets and their incorporation into genome-scale mathematical models
2) Development of genome engineering tools, enabling synthetic biology
3) Application of systems and synthetic biology and genome engineering to improve performance of CHO producers

The training projects are supported by 15 industrial participants, which will participate in the research and test the results. ESR training will include intense courses focused on computational systems biology, cell biology, business and entrepreneurship. The three universities bring unique complementary skills in systems and synthetic biology, ‘omics technologies, cytometry, and molecular cell biology which will provide depth and breadth to this training. The eCHO Systems will produce four major outputs: General knowledge to improve the productivity, quality, and efficiency of CHO platform cell lines, new systems models for CHO cells, new CHO cell line chassises generated through synthetic biology approaches, high quality education at the graduate level, and a cadre of interdisciplinary graduates poised to transform biopharmaceutical biotechnology.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

DANMARKS TEKNISKE UNIVERSITET

Address

Anker Engelundsvej 1 Bygning 101 A
2800 Kgs Lyngby

Denmark

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 160 327,52

Participants (5)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITY OF KENT

United Kingdom

EU Contribution

€ 819 863,64

DUBLIN CITY UNIVERSITY

Ireland

EU Contribution

€ 797 023,80

ACIB GmbH

Austria

EU Contribution

€ 1 017 018,72

RENTSCHLER BIOTECHNOLOGIE GMBH

Germany

UCB PHARMA SA

Belgium

EU Contribution

€ 250 560

Partners (11)

Sort alphabetically

Expand all

UNIVERSITAET FUER BODENKULTUR WIEN

Chorus GmbH

BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

EVERCYTE GMBH

FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED

Symphogen A/S

CMC BIOLOGICS AS

BIONEER A/S

Eli Lilly and Company Limited

ICOSAGEN AS

Janssen Biologics

Project information

Grant agreement ID: 642663

Status

Closed project

  • Start date

    1 January 2015

  • End date

    31 December 2018

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 4 044 794,43

  • EU contribution

    € 4 044 793,68

Coordinated by:

DANMARKS TEKNISKE UNIVERSITET

Denmark